USPTO serial 90346293
Reviewed by CopyMark Law Group
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
LEWES, DE
Port Jefferson, NY
Port Jefferson, NY
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
George Likourezos
George Likourezos CARTER, DELUCA & FARRELL LLP576 BROAD HOLLOW ROADMELVILLE, NY 11747United States| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceuticals, namely, a partial agonist of N-methyl-D-aspartame (NMDA) receptors at low dose and a partial antagonist of NMDA at high dose, an inhibitor of microglial activation, and a modulator of NMDA receptors; antibiotics; pharmaceuticals and antibiotics for the treatment or prevention of neurological symptoms or conditions associated with concussion or traumatic brain injury; pharmaceuticals and antibiotics for reversing the damage caused by concussion or traumatic brain injury | ACTIVE | — |
| 010 | Drug delivery system, namely, an intramuscular autoinjector and an intramuscular drug delivery autoinjector; drug delivery system for administering drugs for the treatment or prevention of neurological symptoms or conditions associated with concussion or traumatic brain injury, namely, an intramuscular autoinjector, and an intramuscular needle-based injection system; an intramuscular needle-based injection system for administering drugs for the treatment or prevention of neurological symptoms or conditions associated with concussion or traumatic brain injury; drug delivery system for reversing the damage caused by concussion or traumatic brain injury, namely, intramuscular autoinjector and an intramuscular needle-based injection system | ACTIVE | — |
| 035 | Retail store services featuring drug delivery systems, pill packets, pharmaceuticals, antibiotics, and drugs for the treatment or prevention of neurological symptoms or conditions associated with concussion or traumatic brain injury | ACTIVE | — |
| 044 | Medical services, namely, providing medical services using drug delivery systems, pill packets, pharmaceuticals, antibiotics, and drugs for the treatment or prevention of neurological symptoms or conditions associated with concussion or traumatic brain injury | ACTIVE | — |
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 2, 2024 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Sep 2, 2024 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Jul 11, 2024 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Feb 1, 2024 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jan 30, 2024 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Jan 30, 2024 | EXT4 | SOU EXTENSION 4 FILED | — |
| Jan 30, 2024 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jul 28, 2023 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jul 26, 2023 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Jul 26, 2023 | EXT3 | SOU EXTENSION 3 FILED | — |
| Jul 26, 2023 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jan 28, 2023 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jan 26, 2023 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Jan 26, 2023 | EXT2 | SOU EXTENSION 2 FILED | — |
| Jan 26, 2023 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jul 16, 2022 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jul 14, 2022 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Jul 14, 2022 | EXT1 | SOU EXTENSION 1 FILED | — |
| Jul 14, 2022 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Feb 1, 2022 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Dec 7, 2021 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Dec 7, 2021 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Nov 17, 2021 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Nov 1, 2021 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Oct 12, 2021 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Oct 12, 2021 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Oct 12, 2021 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Oct 12, 2021 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Oct 12, 2021 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Oct 12, 2021 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Oct 12, 2021 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Oct 12, 2021 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| May 20, 2021 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 20, 2021 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 20, 2021 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 13, 2021 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 3, 2021 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Dec 7, 2020 | TAEA | TEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED | — |
| Dec 7, 2020 | PARI | TEAS VOLUNTARY AMENDMENT RECEIVED | — |
| Dec 2, 2020 | NWAP | NEW APPLICATION ENTERED | — |